<div id="readability-page-1"><div>FULC Investor Alert: Levi &amp; Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud Fulcrum Therapeutics, Inc. lost approximately half its market value after disclosing FDA safety concerns leading the company to discontinue its lead sickle-cell candidate.* Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock plunged roughly 50% on June 1, 2026, following disclosure of an FDA safety concerns related to the PRC2 inhibitor drug class. Those who lost money on FULC are encouraged to submit their information immediately. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The single-session collapse followed Fulcrum’s June 1, 2026 Form 8-K, which revealed the FDA feedback raised concerns about potential malignancy risk associated with PRC2 inhibition. The company simultaneously announced it was discontinuing its lead candidate pociredir and launching a strategic review. Shares that had traded with the expectation of a Phase III sickle-cell program lost half their value before the next morning's open. As recently as April 27, 2026, CEO Alex Sapir told investors on the Q1 2026 earnings call that &#34;pociredir has continued to be generally well tolerated with no treatment-related serious adverse events reported to date&#34; and that Fulcrum believed it held &#34;about a 24-month head start over the next closest competitor.&#34; Approximately five weeks later, Fulcrum announced the discontinuation of the pociredir program following FDA feedback. Levi &amp; Korsinsky is investigating whether Fulcrum adequately disclosed material risks to investors prior to the June 1, 2026 collapse. If you purchased Fulcrum Therapeutics, Inc. shares and suffered a loss, click here to discuss your rights with our team. You may also reach Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. ABOUT THE FIRM -- For over two decades, Levi &amp; Korsinsky has represented shareholders in securities investigations and related actions. Ranked in ISS Top 50 for seven consecutive years. Frequently Asked Questions About the FULC Investigation Q: Who is eligible to participate in the FULC investigation? A: Investors who purchased FULC stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares. Q: How much did FULC stock drop? A: Shares fell approximately 50% in a single session after the company disclosed FDA safety concerns regarding the PRC2 inhibitor drug class, discontinuation of pociredir, and the launch of a strategic review. Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Fulcrum Therapeutics, Inc. made materially false or misleading statements regarding the safety profile and regulatory outlook for pociredir and the PRC2 inhibitor class prior to the June 1, 2026 disclosure. When the FDA safety concern was revealed, the stock price declined sharply. Q: What do FULC investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi &amp; Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation. Q: What if I already sold my FULC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought FULC and sold at a loss may still participate in the investigation. Q: What does it cost me to participate? A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs. Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA2MDQxNTk5ODhyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA2MDQxNTk5ODhyMQ"/> Levi &amp; Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 27th Floor New York, NY 10004 jlevi@levikorsinsky.com Tel: (212) 363-7500 Fax: (212) 363-7171 View source version on businesswire.com: https://www.businesswire.com/news/home/20260604159988/en/</div></div>

FULC

Levi & Korsinsky is investigating Fulcrum Therapeutics (FULC) for potential securities fraud after its stock plunged 50% on June 1, 2026. The drop followed FDA safety concerns regarding malignancy risks linked to the PRC2 inhibitor class, leading Fulcrum to discontinue its lead candidate, pociredir. The firm examines whether prior statements about the drug's safety were misleading.